Plasma Concentrations Of Matrix Metalloproteinase-9 And Plasminogen Activator Inhibitor-1 In Acute Coronary Syndromes

Objective: Matrix metalloproteinases-9(MMP-9) has been implicated in development of atherosclerosis and plaque rupture in acute coronary syndromes (ACS).The aim of the study is to examine the levels of plasma metalloproteinase-9(MMP-9) and plasminogen activator inhibitor-1(PAI-1) or C-reactive protein(CRP) of the patients with acute coronary syndromes(ACS), and to determine the relationships among circulating MMP-9, PAI-1, CRP and coronary artery disease(CAD). The new targets may be useful to evaluate the state of coronary artery disease.It may be useful to provide a new way to treat the patients with ACS.Methods: 84 patients were selected as ACS group, 21 patients as stable angina pectoris (SAP) and 22 persons as in controls.ACS group included 54 patients with unstable angina pectoris (UAP) and 30 patients with acute myocardial infarction(AMI).The blood samples of the control were drown from venous in the morning, and the angina group were drown from venous in the morning of the following day in hospitalization.The concentration of MMP-9 were mensurated by enzyme linked immunesorbent assay(ELISA),and the concentration of CRP were mensurated by immunoturbidimetric method.PAI-1 were measured by ELISA.Theconcentrations of MMP-9, CRP and PAI-1 in each group were compared.Results: Each group's blood samples were evaluated, and the plasmconcentration of MMP-9 from the patients with UAP was 4.91 ±0.40 ng/ml, STEMI 5.35±0.63 ng/ml, NSTEMI 5.19±0.41 ng/ml, SAP 4.61±0.46 ng/ml, CONTROL...